English (UK)
中文版Richard Tao
Fenglin Biomedical Center (BioFM) is an innovation platform based in Xuhui Shanghai, which functions as the China soft-landing gateway for oversea bio-medical companies. It provides working spaces in downtown area in a flexible manner and helps clients increase their business value with professional services and by leveraging innovative resources including academics, hospitals, industries and venture capitals in the region. Different from the traditional accelerators and incubators, BioFM aims to be a boutique and unique service provider especially for bio-medical entrepreneurs, doctors, and scientists, while helping overseas companies and start-ups to develop their business in China quicker and better
Shanghai Fenglin Biomedical Development Co. Ltd
Mr / Project ManagerChao Tu
A startup biotech focusing on novel therapeutic antibody discovery and development, particularly in fully human nanobody and bispecifics. Recently closed a Series A fund raising (USD $25M ).
苏州博奥明赛生物制药有限公司是一家专注于创新生物大分子药的研发型公司。公司已经建立起了多个国际领先的全人源快速抗体发现与优化平台，其中包括国际领先的全人源纳米抗体和双特异性抗体平台以及国际上库容量最大的噬菌体，酵母菌，和哺乳动物细胞展示平台。公司依托平台优势，在较短的时间内已经拥有十多个在研全新生物大分子药物，包括多个国际上首创的全人源纳米抗体（VH）和双特异性抗体。本轮融资资金将主要用于推进其中两个先导项目的临床前开发。
苏州博奥明赛生物制药有限公司是一家专注于创新生物大分子药的研发型公司。公司已经建立起了多个国际领先的全人源快速抗体发现与优化平台，其中包括国际领先的全人源纳米抗体和双特异性抗体平台以及国际上库容量最大的噬菌体，酵母菌，和哺乳动物细胞展示平台。公司依托平台优势，在较短的时间内已经拥有十多个在研全新生物大分子药物，包括多个国际上首创的全人源纳米抗体（VH）和双特异性抗体。本轮融资资金将主要用于推进其中两个先导项目的临床前开发。
Biomissile Biotech
President & CEOLee Vanco
Foncoo was founded in 1999, headquartered in Shenzhen, is a specialty pharmaceutical company with more than 20 years of experience focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases in China.
Our product portfolio covers a range of therapeutic areas including the treatment of psychiatry and neurology diseases, cardiovascular diseases, cancer diseases and Nutritional Medicine.
Our product portfolio covers a range of therapeutic areas including the treatment of psychiatry and neurology diseases, cardiovascular diseases, cancer diseases and Nutritional Medicine.
lh@foncoo.com
BD managerMei Wang
biotech focusing on world leading r&d to solve unmet medical needs
dizal pharmaceutical
team leaderYuqi Wang
QiRun Biotech is focused on Parkinson's disease CDSS research and development. Currently PDCARE program has achieved cooperation With China pharmaceutical university and hospital's support.
QiRun Biotech
Founder
Dr. Weiqing Wang
AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Responsive Web Design powered by 